E. Premkumar Reddy, PhD
img_E. Premkumar Reddy
PROFESSOR | Pharmacological Sciences
PROFESSOR | Oncological Sciences
Research Topics
Autophagy, Cancer, Cancer Genetics, Cell Cycle, Cytokines, Drug Design and Discovery, Knockout Mice, Leukemia, Lymphoma, Oncogenes, Protein Kinases, Signal Transduction, Stem Cells, Transcription Factors, Transgenic Mice, Tumor Suppressor Genes, Viruses and Virology
Multi-Disciplinary Training Area
Cancer Biology [CAB], Disease Mechanisms and Therapeutics (DMT)
Research Interests
Our laboratory is interested in the study of genes that control cell homeostasis and how these controls are dysregulated during the neoplastic process.  We use a combination of biochemistry, molecular biology and synthetic organic chemistry approaches and in close collaboration with the clinical community develop and test small molecule anti-cancer compounds.

We are interested in studying basic biological processes, such as development of the organism through the study of oncogenes such as the myb gene family and cell-cycle regulatory genes such as Cdk4.  We have generated a collection of transgenic and gene knock-out animal models for study of the myb gene family.  Through our studies of the myb gene family, we have begun to understand its role in hematopoietic stem cell development and maintenance and their role in the development of mammary tissue.  We also study the G1 cyclin-dependent kinase, CDK4.  We have developed a nullizygous CDK4 mouse, which displays a phenotype that mimics Type I diabetes, and a CDK4 knock-in mouse that expresses the CDK4R24C protein.  We are using both models to study the role of Cdk4 in the development of cancer.

We also study mechanisms of mitogen activated protein (MAP) kinase signaling through scaffolding proteins belonging to the JIP/JSAP/JLP family.  In 2002, we reported the identification of a MAP kinase scaffolding proteins, JLP, which binds to and coordinately regulates the activities of MEKK3, MKK4, p38MAPK, JNK, Max, c-myc, the kinesin light chain, the stathmin-like protein SCG10, the alpha subumit of the heterotrimeric G protein G13, and the E3 ubiquitin ligase, CHIP.  We are currently undertaking a number of projects aimed at understanding the role of JLP in cell growth and differentiation.

Our basic biology efforts are coordinated with a translational research program to develop and test small molecule anti-cancer therapeutics.  Our chemical biology group has designed and produced a library of nearly 10,000 unique small molecules from approximately 120 individual chemical backbones, or “chemotypes.”  This chemical library has been screened for cytotoxic activity toward cancer cells, while leaving non-malignant tissue intact.  Several of these compounds exhibit kinase inhibitory activities while others seem to inhibit the function of heat shock proteins.  At the present time, we are studying at least 10 such molecules, all with differing mechanisms of action.  Some of these compounds have demonstrated dramatic activity in clinical trials and one of these molecules, ON01910 has been found to have a profound clinical activity in MDS (Myelodysplastic Syndrome) patients.   In combination therapy with Oxaliplatin and Gemcytabine, ON01910 has also been found to have excellent activity in pancreatic and ovarian cancer patients.  Several other kinase inhibitors developed in our laboratory that inhibit Plk2, BCR-ABL, PI3K-a, CK2 have shown pre-clinical activity in cultured cells lines and in animal tumor xenograft models and are being processed for Phase I clinical trials.

The Reddy Laboratory

PhD, Regional Research Laboratories/Osmania University

National Cancer Institute

University of California, School of Medicine


Scientific Achievement Award

American Cancer Society


Laura H. Carnell Professor of Medicine

Temple University

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Reddy during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Company Founder:

  • AACT Inc


  • AACT Inc

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • AACT Inc

Royalty Payments:

  • Onconova Therapeutics, Inc.
  • Miscellaneous Royalties

Scientific Advisory Board:

  • AACT Inc

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.